0|chunk|Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections
0	14	28 salicylanilide	Chemical	CHEBI_239133
0	29	41 anthelmintic	Chemical	CHEBI_35443
0	42	47 drugs	Chemical	CHEBI_23888
0	CHEBI-CHEBI	CHEBI_239133	CHEBI_35443
0	CHEBI-CHEBI	CHEBI_239133	CHEBI_23888
0	CHEBI-CHEBI	CHEBI_35443	CHEBI_23888

1|chunk|The repositioning of drugs already approved by regulatory agencies for other indications is an emerging alternative for the development of new antimicrobial therapies. The repositioning process involves lower risks and costs than the de novo development of novel antimicrobial drugs. Currently, infections by adenovirus show a steady increment with a high clinical impact in immunosuppressed and immunocompetent patients. The lack of a safe and efficacious drug to treat these infections supports the search for new antiviral drugs. Here we evaluated the anti-adenovirus activity of niclosanide, oxyclozanide, and rafoxanide, three salicylanilide anthelmintic drugs. Also, we carried out the cytotoxicity evaluation and partial characterization of the mechanism of action of these drugs. The salicylanilide anthelmintic drugs showed significant anti-adenovirus activity at low micromolar concentrations with little cytotoxicity. Moreover, our mechanistic assays suggest differences in the way the drugs exert anti-adenovirus activity. Niclosamide and rafoxanide target transport of the HAdV particle from the endosome to the nuclear envelope, whilst oxyclozanide specifically targets adenovirus immediately early gene E1A transcription. Data suggests that the studied salicylanilide anthelmintic drugs could be suitable for further clinical evaluation for the development of new antiviral drugs to treat infections by adenovirus in immunosuppressed patients and in immunocompetent individuals with community-acquired pneumonia.
1	21	26 drugs	Chemical	CHEBI_23888
1	143	156 antimicrobial	Chemical	CHEBI_33281
1	263	276 antimicrobial	Chemical	CHEBI_33281
1	277	282 drugs	Chemical	CHEBI_23888
1	457	461 drug	Chemical	CHEBI_23888
1	516	525 antiviral	Chemical	CHEBI_22587
1	516	531 antiviral drugs	Chemical	CHEBI_36044
1	526	531 drugs	Chemical	CHEBI_23888
1	632	646 salicylanilide	Chemical	CHEBI_239133
1	647	659 anthelmintic	Chemical	CHEBI_35443
1	660	665 drugs	Chemical	CHEBI_23888
1	765	771 action	Chemical	CHEBI_5133
1	781	786 drugs	Chemical	CHEBI_23888
1	792	806 salicylanilide	Chemical	CHEBI_239133
1	807	819 anthelmintic	Chemical	CHEBI_35443
1	820	825 drugs	Chemical	CHEBI_23888
1	997	1002 drugs	Chemical	CHEBI_23888
1	1035	1046 Niclosamide	Chemical	CHEBI_7553
1	1268	1282 salicylanilide	Chemical	CHEBI_239133
1	1283	1295 anthelmintic	Chemical	CHEBI_35443
1	1296	1301 drugs	Chemical	CHEBI_23888
1	1379	1388 antiviral	Chemical	CHEBI_22587
1	1379	1394 antiviral drugs	Chemical	CHEBI_36044
1	1389	1394 drugs	Chemical	CHEBI_23888
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_33281
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_36044
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_239133
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_35443
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_5133
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_7553
1	CHEBI-CHEBI	CHEBI_33281	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_33281	CHEBI_36044
1	CHEBI-CHEBI	CHEBI_33281	CHEBI_239133
1	CHEBI-CHEBI	CHEBI_33281	CHEBI_35443
1	CHEBI-CHEBI	CHEBI_33281	CHEBI_5133
1	CHEBI-CHEBI	CHEBI_33281	CHEBI_7553
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_36044
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_239133
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_35443
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_5133
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_7553
1	CHEBI-CHEBI	CHEBI_36044	CHEBI_239133
1	CHEBI-CHEBI	CHEBI_36044	CHEBI_35443
1	CHEBI-CHEBI	CHEBI_36044	CHEBI_5133
1	CHEBI-CHEBI	CHEBI_36044	CHEBI_7553
1	CHEBI-CHEBI	CHEBI_239133	CHEBI_35443
1	CHEBI-CHEBI	CHEBI_239133	CHEBI_5133
1	CHEBI-CHEBI	CHEBI_239133	CHEBI_7553
1	CHEBI-CHEBI	CHEBI_35443	CHEBI_5133
1	CHEBI-CHEBI	CHEBI_35443	CHEBI_7553
1	CHEBI-CHEBI	CHEBI_5133	CHEBI_7553

